Document Details

(2 mb)

OSTEOGENIC SARCOMA - IMMUNOLOGIC PARAMETERS BEFORE AND DURING IMMUNOTHERAPY WITH TUMOR-SPECIFIC TRANSFER FACTOR ( THE JOURNAL OF CLINICAL INVESTIGATION, VOL. 55, MARCH 1975, 487-499 ) ( PARTIAL )

BYERS, V S; FUDENBERG, H H; HACKETT, A J; JOHNSTON, J O; LEVIN, A S; SPITLER, L E; WYBRAN, J

HREX; PLUTONIUM INJECTION EXPERIMENT

Location - DOE/NNSA NUCLEAR TESTING ARCHIVE Address - P.O. Box 98521 City - Las Vegas State - NV Zip - 89193-8521 Phone - (702)794-5106 Fax - (702)862-4240 Email - NTA@NV.DOE.GOV

JOURNAL ARTICLE

1975 Mar 31

Never classified

0027

NV0702314

JOURNAL OF CLINICAL INVESTIGATIONS

1994 Aug 27

2017 Dec 21

EIGHTEEN PATIENTS WITH OSTEOGENIC SARCOMA WERE FOLLOWED BY SERIAL MEASUREMENTS IN VITRO OF TUMOR-SPECIFIC CELL-MEDIATED CYTOTOXICITY AND OF "ACTIVE" AND TOTAL ROSETTE-FORMING T-CELLS. THIRTEEN OF THESE PATIENTS HAVE HAD OR ARE CURRENTLY RECEIVING INJECTIONS OF OSTEOGENIC SARCOMA-SPECIFIC DIALYZABLE TRANSFER FACTOR DERIVED FROM HEALTHY DONORS. IN 3 PATIENTS WITH VERY SMALL LESIONS, CYTOTOXICITY WAS HIGH BEFORE AMPUTATION AND DECREASED WITHIN 2 MONTHS AFTER TUMOR REMOVAL. CYTOTOXICITY WAS LOW AT TIME OF DIAGNOSIS IN ALL PATIENTS WITH LARGE TUMOR MASSES. THE CYTOTOXICITY OF THE PATIENTS' LYMPHOCYTES INCREASED AFTER ADMINISTRATION OF TUMOR-SPECIFIC TRANSFER FACTOR IN ALL PATIENTS SO TREATED. PATIENTS RECEIVING NONSPECIFIC TRANSFER FACTOR SHOWED EVIDENCE OF DECLINING CELL-MEDIATED CYTOTOXICITY. TUMOR-SPECIFIC TRANSFER FACTOR MAY PRODUCE AN INCREASE IN CELL MEDIATED CYTOTOXICITY TO THE TUMOR IN PATIENTS WITH OSTEOGENIC SARCOMA. THIS POSSIBILITY IS SUGGESTED BY THE PAIN AND EDEMA THAT OCCURRED IN THE AREA OF THE TUMOR IN PATIENTS WHO HAD METASTATIC DISEASE WHEN THERAPY WAS STARTED AND LYMPHOCYTIC INFILTRATES IN THE TUMOR, AS WELL AS BY THE INCREASE IN CELL-MEDIATED CYTOTOXICITY AND THE INCREASE IN PERCENTAGE OF ACTIVE ROSETTE-FORMING CELLS FROM SUBNORMAL TO NORMAL. SERIAL MEASUREMENTS OF CELL-MEDIATED CYTOTOXICITY ARE HELPFUL IN MONITORING THE EFFICACY OF TRANSFER FACTOR AND OTHER MODES OF THERAPY IN THESE PATIENTS, AND THESE MEASUREMENTS ARE THE BEST AVAILABLE CRITERIA FOR SELECTION OF TUMOR-SPECIFIC TRANSFER FACTOR.